Pharming Group (NASDAQ:PHAR) Shares Gap Down to $8.43

Shares of Pharming Group (NASDAQ:PHAR) gapped down prior to trading on Friday . The stock had previously closed at $8.43, but opened at $8.17. Pharming Group shares last traded at $8.34, with a volume of 516 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Friday, May 31st.

Pharming Group Stock Down 0.4 %

The business has a fifty day moving average of $8.90 and a two-hundred day moving average of $10.55.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.20). Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. The firm had revenue of $55.59 million for the quarter, compared to analysts’ expectations of $68.43 million. Analysts forecast that Pharming Group will post -0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC purchased a new stake in Pharming Group (NASDAQ:PHAR) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.